Synthesis and Preclinical Evaluation of the Fibrin-Binding Cyclic Peptide ¹⁸F-iCREKA: Comparison with Its Contrasted Linear Peptide

Figure 4

(a) Binding affinity of ¹⁸F-NOTA-CREKA, ¹⁸F-NOTA-LP, and ¹⁸F-NOTA-iCREKA to U87MG cells; (b) binding affinity of ¹⁸F-NOTA-CREKA, ¹⁸F-NOTA-LP, and ¹⁸F-NOTA-iCREKA to Caov3 cells; (c) confocal microscope analyses of FITC-LP and FITC-iCREKA in U87MG and Caov3 cells; (d) pathological verifications of the U87MG xenograft and Caov3 xenograft. The first column was H&E staining for U87MG xenograft and Caov3 xenograft, and the second column was immunohistochemical staining of MMP-2/9 expression for U87MG xenograft and Caov3 xenograft. The MMP-2/9 was highly expressed in U87MG tumor tissues (the brown portions) and was extremely lowly expressed in Caov3 tumor tissues.

(a)

(b)

(c)

(d)